期刊文献+

高三尖杉酯碱联合survivin抑制剂YM155对人白血病K562细胞系增殖和凋亡的影响 被引量:1

Effects of homharringtonine plus survivin inhibitor YM155 on the proliferation and apoptosis of human leukemia cell line K562
原文传递
导出
摘要 目的:探讨高三尖杉酯碱(HHT)联合survivin抑制剂YM155对人白血病K562细胞系增殖抑制和诱导凋亡的作用及机制。方法:CCK法检测细胞增殖抑制率,依据中效原理及CalcuSyn软件评价HHT和YM155的联合治疗效果。设空白对照组、HHT组、YM155组和联合用药组,采用Annexin V/PI双染法以流式细胞仪检测细胞凋亡率,Western blot法检测survivin蛋白变化,以特异性荧光底物检测caspase-3、-8活性变化。结果:HHT和YM155单药均以浓度依赖方式抑制K562细胞生长,二者联合应用具有化疗协同作用(CI<1)。联合用药组K562细胞凋亡率明显高于单独用药组,且survivin蛋白表达显著下调(均P<0.05)。HHT单药及联合用药组诱导caspase-3、-8活化,而YM155单药未引起caspase-3、-8活性变化。结论:HHT和YM155联合应用于K562细胞具有化疗协同作用,通过下调survivin诱导K562细胞凋亡。 Objectives: To explore the combination applications of homharringtonine (HHT) and the survivin inhibitor YM155 on the proliferation and apoptosis of human leukemia cell line K562 and its mechanism. Methods: CCK-8 assay was used to determine the growth inhibition. The combination index CI of HHT and YM155 was cal- culated using the Chou-talalay methods by CalcuSyn software. The cells were divided into 4 groups:control group, HHT group,YM155 group,and combination group. The cell apoptosis rates were evaluated by flow cytometry. The expressions of associated proteins were detected by Western blot. Caspase-3 and -8 activities were determined using the specific fluorogenic substrates. Results: The inhibitory rates on cell growth by HHT and YM155 alone in creased in concertration-dependent manner. The application of H HT and YM155 had synergistic effect (CI〈1). The apoptosis rate was higher in combination group than those of one drug group and the protein expression levels of survivin decreased remarkably in combination group (P〈0.05). Caspase-3 and -8 were activated by HHT or combination treatment, but not by YM155. Conclusion: The combination treatment with HHT and YM155 on K562 cells has synergistic effect. The mechanism is related to the apoptosis induced through down-regulation of survivin.
出处 《临床血液学杂志》 CAS 2015年第2期209-211,214,共4页 Journal of Clinical Hematology
基金 浙江省中医药科技计划项目(No:2012ZB159) 绍兴市公益性应用计划项目(No:2012B70066)
关键词 高三尖杉酯碱 YM155 K562细胞 homharringtonine YM155 K562 cells
  • 相关文献

参考文献12

  • 1封蔚莹,周炀,钟永根,傅佳萍.SN-38对K562细胞的增殖抑制、凋亡诱导及其与塞来昔布联合化疗的协同作用[J].华中科技大学学报(医学版),2012,41(2):156-160. 被引量:4
  • 2封蔚莹,周炀,周国忠.Survivin反义寡核苷酸诱导K562细胞凋亡及化疗协同作用研究[J].临床血液学杂志,2012,25(4):454-456. 被引量:3
  • 3Nakahara T,Kita A,Yamanaka K,et al.YM155,a novel small-molecule survivin suppressant,induces regression of established human hormone-refractory prostate tumor xenografts[J].Cancer Res,2007,67:8014-8021.
  • 4Yamauchi T,Nakamura N,Hiramoto M,et al.Sepantronium bromide(YM155)induces disruption of the ILF3/p54(nrb)complex,which is required for survivin expression[J].Biochem Biophys Res Commun,2012,425:711-716.
  • 5Feng W,Yoshida A,Ueda T.YM155induces caspase-8dependent apoptosis through downregulation of survivin and Mcl-1in human leukemia cells[J].Biochem Biophys Res Commun,2013,435:52-57.
  • 6Tang H,Shao H,Yu C,et al.Mcl-1downregulation by YM155contributes to its synergistic anti-tumor activities with ABT-263[J].Biochem Pharmacol,2011,82:1066-1072.
  • 7Na YS,Yang SJ,Kim SM,et al.YM155induces EGFR suppression in pancreatic cancer cells[J].PLoS One,2012,7:e38625.
  • 8Wang YF,Zhang W,HE KF,et al.Induction of autophagy-dependent cell death by the survivin suppressant YM155in salivary adenoid cystic carcinoma[J].Apoptosis,2014,19:748-758.
  • 9Kaneko N,Mitsuoka K,Amino N,et al.Combination of YM155,a survivin suppressant,with bendamustine and rituximab:a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma[J].Clin Cancer Res,2014,20:1814-1822.
  • 10Kaneko N,Kita A,Yamanaka K,et al.Combination of YM155,a survivin suppressant with a STAT3inhibitor:a new strategy to treat diffuse large B-cell lymphoma[J].Leuk Res,2013,37:1156-1161.

二级参考文献24

  • 1贺芳,曾耀英,王通,邢飞跃,林羿,梁佩燕,肇静娴.喜树碱诱导的HL-60细胞凋亡过程中线粒体的变化[J].细胞与分子免疫学杂志,2006,22(2):144-147. 被引量:1
  • 2Ramesh M,Ahlawat P,Srinivas N R.Irinotecan and its active metabolite,SN-38:review of bioanalytical methods and recent update from clinical pharmacology perspectives[J].Biomed Chromatogr,2010,24(1):104-123.
  • 3Chou T C.Drug combination studies and their synergy quantification using the Chou-Talalay method[J].Cancer Res,2010,70(2):440-446.
  • 4Inoue Y,Tanaka K,Hiro J,et al.In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer[J].Int J Oncol,2006,28(2):479-486.
  • 5Horiike A,Kudo K,Miyauchi E,et al.Phase Ⅰ study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer[J].Br J Cancer,2011,105(8):1131-1116.
  • 6Adams D J,Sandvold M L,Myhren F,et al.Anti proliferative activity of ELACY(CP-4055)in combination with cloretazine(VNP40101M),idarubicin,gemcitabine,irinotecan and topotecan in human leukemia and lymphoma cells[J].Leuk Lymphoma,2008,49(4):786-797.
  • 7Minderman H,O'Loughlin K L,Smith P F,et al.Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia[J].Cancer Chemother Pharmacol,2006,57(1):73-83.
  • 8Wallin A,Svanvik J,Holmlund B,et al.Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential[J].Oncol Rep,2008,19(6):1493-1498.
  • 9Gupta V,Su Y S,Samuelson C G,et al.Irinotecan:a potential new chemotherapeutic agent for atypical or malignant meningiomas[J].J Neurosurg,2007,106(3):455-462.
  • 10Liu Y,Xing H,Weng D,et al.Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer[J].Cancer Lett,2009,274(1):47-53.

共引文献3

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部